We will continue to develop and deliver valuable treatments for patients around the world living with FOP and other rare diseases. Blueprint also develops cancer drugs – it is developing ...
Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.
“People living with FOP lack adequate treatment options, and dosing of the first participant in the ANDECAL trial is a significant milestone in our mission to address their needs. Andecaliximab ...
To determine whether these findings may have implications as potential FOP treatments, the researchers employed genetic and pharmacologic approaches to demonstrate the critical contribution of BMP ...
The FOP contract gives officers who were first time offenders the option to resign, retire or enter mandatory substance abuse ...
ANDECAL study, a Phase 2/3 clinical trial evaluating the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP ...